이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

국소 진행성 또는 전이성 비소세포폐암에서 아미반타맙 및 레이저티닙 병용 요법과 오시머티닙 비교 연구 (MARIPOSA)

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

EGFR 돌연변이 국소 진행성 또는 전이성 비소세포폐암 환자의 1차 치료로서 아미반타맙 및 레이저티닙 병용 요법 대 오시머티닙 대 레이저티닙의 3상 무작위 연구.

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

연구 개요

연구 유형

중재적

등록 (실제)

1074

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • 's-Hertogenbosch, 네덜란드, 5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Arnhem, 네덜란드, 6815 AD
        • Rijnstate Ziekenhuis
      • Harderwijk, 네덜란드, 3844 DG
        • Ziekenhuis St Jansdal
      • Nijmegen, 네덜란드, 6525AG
        • UMC Radboud
      • Kaohsiung City, 대만, 807
        • Kaohsiung Medical University Chung Ho Memorial Hospital
      • Kaohsiung City, 대만, 833
        • Chang Gung Medical Foundation
      • Kaohsiung City, 대만, 824
        • E-DA Hospital
      • New Taipei City, 대만, 23561
        • Taipei Medical University Shuang Ho Hospital
      • Taichung, 대만, 40447
        • China Medical University Hospital
      • Taichung, 대만, 402
        • Chung Shan Medical University Hospital
      • Tainan, 대만, 704
        • National Cheng Kung University Hospital
      • Taipei, 대만, 10002
        • National Taiwan University Hospital
      • Busan, 대한민국, 48108
        • Inje University Haeundae Paik Hospital
      • Cheongju-si, 대한민국, 28644
        • Chungbuk National University Hospital
      • Seongnam-si, 대한민국, 13620
        • Seoul National University Bundang Hospital
      • Seoul, 대한민국, 05505
        • Asan Medical Center
      • Seoul, 대한민국, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, 대한민국, 06351
        • Samsung Medical Center
      • Seoul, 대한민국, 03181
        • Kangbuk Samsung Hospital
      • Seoul, 대한민국, 06591
        • The Catholic University of Korea Seoul St Mary s Hospital
      • Seoul, 대한민국, 8308
        • Korea University Guro Hospital
      • Bad Berka, 독일, 99437
        • Zentralklinik Bad Berka GmbH
      • Berlin, 독일, 14165
        • Helios Klinikum Emil von Behring GmbH
      • Cologne, 독일, 51109
        • Kliniken der Stadt Koeln gGmbH
      • Essen, 독일, 45147
        • Universitaetsklinikum Essen
      • Gauting, 독일, 82131
        • Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
      • Halle, 독일, 06120
        • Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
      • Heidelberg, 독일, 69126
        • Thoraxklinik am Universitatsklinikum Heidelberg
      • Heilbronn, 독일, 74072
        • Onkologische Schwerpunktpraxis
      • Leipzig, 독일, 04357
        • POIS Leipzig GbR
      • Oldenburg, 독일, 26121
        • Pius-Hospital Oldenburg
      • Stuttgart, 독일, 70376
        • Robert-Bosch-Krankenhaus - Klinik Schillerhoehe
      • Irkutsk, 러시아 제국, 664035
        • Irkutsk Regional Oncology Dispensary
      • Krasnoyarsk, 러시아 제국, 660133
        • Krasnoyarsk Regional Oncology Dispensary
      • Kuzmolovsky, 러시아 제국, 188663
        • Leningrad Regional Oncology Dispensary
      • Moscow, 러시아 제국, 115533
        • MCK
      • Moscow, 러시아 제국, 121205
        • Moscow City Oncology Hospital No 62
      • Nal'chik, 러시아 제국, 360000
        • City Clinical Hospital #1
      • Nizhny Novgorod, 러시아 제국, 603000
        • Nizhny Novgorod Regional Oncological Dispensary
      • Omsk, 러시아 제국, 664013
        • Omsk Clinical Oncology Dispensary
      • Saint Petersburg, 러시아 제국, 197758
        • N.N. Petrov Research Institute Of Oncology
      • Saint Petersburg, 러시아 제국, 196006
        • Oncology Medical Clinics AV Medical group
      • Saint Petersburg, 러시아 제국, 190121
        • Current medical technologies
      • Tambov, 러시아 제국, 392013
        • Tambov Regional Oncology Clinical Dispansary
      • Tomsk, 러시아 제국, 634050
        • Tomsk Cancer Research Institute
      • Ufa, 러시아 제국, 450083
        • Bashkir State Medical University
      • Yaroslavl, 러시아 제국, 150054
        • Yaroslavl Regional Clinical Oncology Hospital
      • George Town, 말레이시아, 10990
        • Hospital Pulau Pinang
      • Johor Bahru, 말레이시아, 81100
        • Hospital Sultan Ismail
      • Kuala Lumpur, 말레이시아, 50586
        • Hospital Kuala Lumpur
      • Kuala Lumpur, 말레이시아, 59100
        • University Malaya Medical Centre
      • Kuantan, 말레이시아, 25100
        • Hospital Tengku Ampuan Afzan
      • Petaling Jaya, 말레이시아, 46050
        • Beacon Hospital Sdn Bhd
      • Guadalajara, 멕시코, 44280
        • Hospital Civil de Guadalajara Fray Antonio Alcalde
      • León, 멕시코, 37000
        • CIMOVA, Morals Vargas Centro de Investigación SC
      • Mexico City, 멕시코, 14050
        • Médica Sur
      • Mexico City, 멕시코, 03100
        • Mexico Centre for Clinical Research, S.A. de C.V.
      • Monterrey, 멕시코, 64710
        • i Can Oncology Center
      • México, 멕시코, 14080
        • Instituto Nacional de Cancerologia
      • México, 멕시코, 03100
        • Health Pharma Professional Research
      • Naucalpan, 멕시코, 53100
        • Oncologia Integral Satelite
    • Arizona
      • Goodyear, Arizona, 미국, 85395
        • Arizona Oncology Associates, PC - HAL
      • Yuma, Arizona, 미국, 85364
        • Yuma Regional Medical Center
    • California
      • Long Beach, California, 미국, 90813
        • City of Hope Long Beach Elm
      • Orange, California, 미국, 92868
        • University of California Irvine
    • Colorado
      • Lone Tree, Colorado, 미국, 80124
        • Rocky Mountain Cancer Centers
    • Florida
      • Jacksonville, Florida, 미국, 32256
        • Cancer Specialists of North Florida
    • Georgia
      • Athens, Georgia, 미국, 30607
        • University Cancer And Blood Center LLC
    • Louisiana
      • Metairie, Louisiana, 미국, 70006
        • East Jefferson General Hospital
    • Maryland
      • Columbia, Maryland, 미국, 21044
        • Maryland Oncology Hematology, PA
    • Michigan
      • Detroit, Michigan, 미국, 48202
        • Henry Ford Hospital
    • Minnesota
      • Edina, Minnesota, 미국, 55435
        • Minnesota Oncology Hematology P A
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • Washington University School Of Medicine
    • New Jersey
      • East Brunswick, New Jersey, 미국, 08816
        • Astera Cancer Care
    • Oregon
      • Eugene, Oregon, 미국, 97401
        • Willamette Valley Cancer Institute and Research Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, 미국, 15232
        • University of Pittsburgh Medical Center
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • Sarah Cannon Research Institute
    • Texas
      • Austin, Texas, 미국, 78745
        • Texas Oncology P A
      • Houston, Texas, 미국, 77030
        • Oncology Consultants Texas
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Virginia Cancer Specialists
      • Brussels, 벨기에, 1200
        • Cliniques Universitaires Saint Luc
      • Charleroi, 벨기에, 6060
        • Grand Hopital De Charleroi Site Les Viviers
      • Leuven, 벨기에, 3000
        • UZ Leuven
      • Ottignies, 벨기에, 1340
        • Clinique Saint Pierre
      • Roeselare, 벨기에, 8800
        • Algemeen Ziekenhuis Delta
      • Barretos, 브라질, 14784-400
        • Fundacao Pio XII
      • Belo Horizonte, 브라질, 30110-022
        • Cetus Oncologia
      • Florianópolis, 브라질, 88020-210
        • Ynova Pesquisa Clinica
      • Ijuí, 브라질, 98700-000
        • Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
      • Natal, 브라질, 59062 000
        • Liga Norte Riograndense Contra O Cancer
      • Pelotas, 브라질, 96020 080
        • UPCO Unidade de Pesquisa Clinica em Oncologia
      • Porto Alegre, 브라질, 90020-090
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, 브라질, 90610-000
        • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
      • Rio de Janeiro, 브라질, 22 250 905
        • Oncoclinicas Rio de Janeiro S A
      • Rio de Janeiro, 브라질, 20231 050
        • Ministerio da Saude Instituto Nacional do Cancer
      • Rio de Janeiro, 브라질, 22281 100
        • IDOR - Regional Rio de Janeiro
      • Sorocaba, 브라질, 18030-075
        • IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
      • São Paulo, 브라질, 04014-002
        • Núcleo de Pesquisa São Camilo
      • São Paulo, 브라질, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, 브라질, 01246 000
        • Fundacao Faculdade de Medicina Instituto do Cancer do Estado de Sao Paulo
      • Vitória, 브라질, 29308-014
        • Hospital Evangélico de Cachoeiro de Itapemirim
      • A Coruña, 스페인, 15006
        • Hosp Univ A Coruna
      • Badalona, 스페인, 08916
        • Inst. Cat. D'Oncologia-Badalona
      • Barcelona, 스페인, 08025
        • Hosp. de La Santa Creu I Sant Pau
      • Barcelona, 스페인, 08028
        • Hosp. Univ. Quiron Dexeus
      • Barcelona, 스페인, 08035
        • Hosp Univ Vall D Hebron
      • Burgos, 스페인, 09003
        • Hosp. Univ. de Burgos
      • Girona, 스페인, 17007
        • Institut Català D'Oncologia Girona
      • Madrid, 스페인, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, 스페인, 28046
        • Hosp. Univ. La Paz
      • Madrid, 스페인, 28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Majadahonda, 스페인, 28222
        • Hosp. Univ. Pta. de Hierro Majadahonda
      • Málaga, 스페인, 29011
        • Hosp Regional Univ de Malaga
      • Pamplona, 스페인, 31008
        • Clinica Univ. de Navarra
      • Seville, 스페인, 41013
        • Hosp. Virgen Del Rocio
      • Valencia, 스페인, 46014
        • Hosp. Gral. Univ. Valencia
      • Zaragoza, 스페인, 50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Buenos Aires, 아르헨티나, C1428ANZ
        • Instituto Alexander Fleming
      • Buenos Aires, 아르헨티나, C1426AGE
        • Centro Oncológico Korben
      • Córdoba, 아르헨티나, X5016KEH
        • Hospital Privado Centro Medico de Cordoba
      • La Rioja, 아르헨티나, F5300COE
        • Centro Oncologico Riojano Integral (Cori)
      • Viedma, 아르헨티나, R8500ACE
        • Clínica Viedma
      • Edinburgh, 영국, EH4 2XU
        • Edinburgh Cancer Centre Western General
      • London, 영국, NW1 2PG
        • UCL Cancer Institute
      • London, 영국, SW3 6JJ
        • The Royal Marsden NHS Trust
      • London, 영국, SW10 9NH
        • Chelsea And Westminster Hospital
      • Manchester, 영국, M20 4BX
        • Christie NHS Foundation Trust
      • Nottingham, 영국, NG5 1PB
        • Nottingham University Hospitals NHS Trust
      • Sutton, 영국, SM2 5PT
        • The Royal Marsden NHS Trust 1
      • Dnipro, 우크라이나, 49102
        • Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
      • Kharkiv, 우크라이나, 61070
        • Municipal non-profit enterprise 'Regional Center of Oncology'
      • Kyiv, 우크라이나, 02091
        • Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
      • Kyiv, 우크라이나, 03022
        • State Nonprofit Enterprise National Cancer Institute
      • Uzhhorod, 우크라이나, 88000
        • Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal
      • Haifa, 이스라엘, 3109601
        • Rambam Health Corporation
      • Jerusalem, 이스라엘, 9112001
        • Hadassah Medical Center
      • Kfar Saba, 이스라엘, 44281
        • Meir Medical Center
      • Petah Tikva, 이스라엘, 49100
        • Rabin Medical Center
      • Ramat Gan, 이스라엘, 5262100
        • Chaim Sheba Medical Center
      • Tel Aviv, 이스라엘, 6423906
        • Tel Aviv Sourasky Medical Center
      • Avellino, 이탈리아, 83100
        • Ospedale San Giuseppe Moscati di Avellino
      • Catania, 이탈리아, 95123
        • Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
      • Meldola, 이탈리아, 47014
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
      • Milan, 이탈리아, 20141
        • Istituto Europeo di Oncologia
      • Milan, 이탈리아, 20132
        • IRCCS Ospedale San Raffaele
      • Milan, 이탈리아, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Milan, 이탈리아, 20122
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
      • Monza, 이탈리아, 20052
        • San Gerardo Hospital
      • Naples, 이탈리아, 80100
        • Ospedale Monaldi
      • Orbassano, 이탈리아, 10043
        • Aou San Luigi Gonzaga
      • Ravenna, 이탈리아, 48121
        • Ospedale S. Maria Delle Croci
      • Roma, 이탈리아, 00168
        • Irccs Gemelli
      • Rozzano, 이탈리아, 20089
        • Istituto Clinico Humanitas
      • Hyderabad, 인도, 500034
        • Basavatarakam Indo-American Hospital
      • Kolkata, 인도, 700160
        • Tata Medical Center
      • Mumbai, 인도, 400012
        • Tata Memorial Hospital
      • Nashik, 인도, 422002
        • HCG Manavta Cancer Centre
      • Pune, 인도, 411013
        • Noble Hospital Pvt Ltd
      • Bunkyō City, 일본, 113 8431
        • Juntendo University Hospital
      • Chūōku, 일본, 104 0045
        • National Cancer Center Hospital
      • Fukuoka, 일본, 810-8563
        • National Hospital Organization Kyushu Medical Center
      • Himeji, 일본, 670-8520
        • National Hospital Organization Himeji Medical Center
      • Hirakata, 일본, 573 1191
        • Kansai Medical University Hospital
      • Kanazawa, 일본, 920 8641
        • Kanazawa University Hospital
      • Kashiwa, 일본, 277 8577
        • National Cancer Center Hospital East
      • Kurume, 일본, 830-0011
        • Kurume University Hospital
      • Matsusaka, 일본, 515-8544
        • Matsusaka Municipal Hospital
      • Niigata, 일본, 951-8566
        • Niigata Cancer Center Hospital
      • Okayama, 일본, 700 8558
        • Okayama University Hospital
      • Osaka Sayama Shi, 일본, 589 8511
        • Kindai University Hospital
      • Shibukawa, 일본, 377-0280
        • National Hospital Organization Shibukawa Medical Center
      • Tokyo, 일본, 135 8550
        • The Cancer Institute Hospital of JFCR
      • Tokyo, 일본, 152 8902
        • National Hospital Organization Tokyo Medical Center
      • Toon-shi, 일본, 791-0295
        • Ehime University Hospital
      • Toyonaka-shi, 일본, 560-8552
        • National Hospital Organization Osaka Toneyama Medical Center
      • Wakayama, 일본, 641 8510
        • Wakayama Medical University Hospital
      • Yamaguchi, 일본, 740-8510
        • National Hospital Organization Iwakuni Clinical Center
      • Yamaguchi, 일본, 755-0241
        • National Hospital Organization Yamaguchi Ube Medical Center
      • Beijing, 중국, 100853
        • Chinese PLA General Hospital
      • Beijing, 중국, 100050
        • Beijing Friendship Hospital Capital Medical University
      • Beijing, 중국, 100142
        • Beijing Cancer Hospital Respiratory Medicine Department II
      • Beijing, 중국, 100142
        • Beijing Cancer Hospital Respiratory Medicine Department I
      • Beijing, 중국, 101149
        • Beijing Chest hospital, Capital medical university
      • Changchun, 중국, 130000
        • Jilin cancer hospital
      • Changsha, 중국, 410013
        • Hunan Cancer hospital Thoracic Medicine Department II
      • Changsha, 중국, 410013
        • Hunan Cancer hospital Thoracic Medicine Department I
      • Changzhou, 중국, 213003
        • The First People's Hospital Of Changzhou
      • Chengdu, 중국, 610041
        • Sichuan Cancer Hospital
      • Chengdu, 중국, 610041
        • West China Hospital Sichuan University
      • Chongqing, 중국, 400038
        • Southwest Hospital
      • Guangzhou, 중국, 510080
        • The First Affiliated Hospital Sun Yat sen University
      • Guangzhou, 중국, 510120
        • Sun Yat-Sen Memorial Hospital Sun Yat-sen University
      • Hangzhou, 중국, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, 중국, 310009
        • Second Affiliated Hospital, School of Medicine, Zhejiang University
      • Hangzhou, 중국, 310009
        • The Second Affiliated Hospital of Zhejiang University College of Medicine
      • Hangzhou, 중국, 310016
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Harbin, 중국, 150000
        • Harbin medical university cancer hospital
      • Huizhou, 중국, 516001
        • Huizhou Municipal Central Hospital
      • Linhai, 중국, 317000
        • Taizhou Hospital of Zhejiang Province
      • Nantong, 중국, 226300
        • Nantong Tumor Hospital
      • Shanghai, 중국, 200030
        • Shanghai Chest Hospital
      • Shanghai, 중국, 200032
        • Fudan University Shanghai Cancer Center
      • Shanghai, 중국, 200123
        • Shanghai East Hospital
      • Shanghai, 중국, 200025
        • Ruijin Hospital Shanghai Jiao Tong University
      • Shenyang, 중국, 110004
        • Shengjing Hospital Of China Medical University
      • Tianjin, 중국, 300052
        • Tianjin Medical University General Hospital
      • Wenzhou, 중국, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, 중국, 430030
        • TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
      • Xi'an, 중국, 710061
        • The First Affiliated Hospital of Xian Jiaotong University
      • Yantai, 중국, 264000
        • Yantai Yuhuangding Hospital
      • Zhengzhou, 중국, 450008
        • Henan Cancer Hospital
      • Ürümqi, 중국, 830000
        • Cancer Hospital of Xinjiang Medical University
    • Ontario
      • Brampton, Ontario, 캐나다, L6R 3J7
        • William Osler Health System
      • Hamilton, Ontario, 캐나다, L8V 5C2
        • Juravinski Cancer Centre
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • The Ottawa Hospital Cancer Centre
    • Quebec
      • Montreal, Quebec, 캐나다, H4A 3J1
        • McGill University Health Centre
      • Bangkok, 태국, 10700
        • Siriraj Hospital
      • Bangkok, 태국, 10400
        • Phramongkutklao Hospital and Medical College
      • Chiang Mai, 태국, 50200
        • Chiang Mai University
      • Songkhla, 태국, 90110
        • Songklanagarind Hospital, Prince of Songkla University
      • Adana, 터키 (Türkiye), 01060
        • Adana City Hospital
      • Adana, 터키 (Türkiye), 01250
        • Başkent University Medical Faculty Adana Application and Research Center
      • Ankara, 터키 (Türkiye), 6800
        • Ankara Bilkent City Hospital
      • Ankara, 터키 (Türkiye), 06560
        • Gazi Hastanesi
      • Edirne, 터키 (Türkiye), 22030
        • Trakya University Medical Faculty
      • Istanbul, 터키 (Türkiye), 34098
        • Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
      • Istanbul, 터키 (Türkiye), 34722
        • T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
      • Istanbul, 터키 (Türkiye), 34214
        • Medipol Mega University Hospital
      • Izmir, 터키 (Türkiye), 35575
        • Medical Point
      • Konya, 터키 (Türkiye), 42080
        • Necmettin Erbakan University Meram Medical Faculty
      • Lisbon, 포르투갈, 1769-001
        • Uls Santa Maria - Hosp. Pulido Valente
      • Porto, 포르투갈, 4200-072
        • Instituto Portugues de Oncologia
      • Porto, 포르투갈, 4099-001
        • Uls Santo Antonio - Hosp. Santo Antonio
      • Porto, 포르투갈, 4100 180
        • Hosp. Cuf Porto
      • Bydgoszcz, 폴란드, 85 796
        • Centrum Onkologii im Prof F Lukaszczyka
      • Gdansk, 폴란드, 80 214
        • Uniwersyteckie Centrum Kliniczne
      • Gdynia, 폴란드, 81 519
        • Szpitale Pomorskie Sp z o o
      • Olsztyn, 폴란드, 10-357
        • Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
      • Poznan, 폴란드, 60-693
        • Private Specialist Hospitals - MedPolonia
      • Warsaw, 폴란드, 02-781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Rio Piedras, 푸에르토 리코, 00935
        • Pan American Center for Oncology Trials LLC
      • Bordeaux, 프랑스, 33000
        • Institut Bergonie
      • Bron, 프랑스, 69500
        • Hospices Civils de Lyon HCL
      • La Tronche, 프랑스, 38700
        • CHU de Grenoble Hopital Albert Michallon
      • Lille, 프랑스, 59000
        • Institute Coeur Poumon
      • Limoges, 프랑스, 87000
        • CHU de Limoges
      • Marseille, 프랑스, 13915
        • Hopital Nord
      • Paris, 프랑스, 75005
        • Institut Curie
      • Paris, 프랑스, 75970
        • Hopital Tenon
      • Pessac, 프랑스, 33604
        • CHU Bordeaux
      • Sain-Herblain, 프랑스, 44800
        • CHU Nantes
      • Saint-Mandé, 프랑스, 94163
        • HIA Begin
      • Tours, 프랑스, 37000
        • CHU Bretonneau
      • Villejuif, 프랑스, 94805
        • Institut Gustave Roussy
      • Budapest, 헝가리, H-1529
        • Orszagos Koranyi Tbc es Pulmonologiai Intezet
      • Farkasgyepü, 헝가리, 8582
        • Veszprém Megyei Tudőgyógyintézet
      • Gyöngyös, 헝가리, 3233
        • Mátrai Gyógyintézet-Bronchológia
      • Szombathely, 헝가리, 9700
        • Markusovszky Egyetemi Oktatokorhaz
      • Székesfehérvár, 헝가리, 8000
        • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
      • Törökbálint, 헝가리, 2045
        • Tudogyogyintezet Torokbalint
      • Bedford Park, 호주, 5042
        • Flinders Medical Centre
      • Heidelberg, 호주, 3084
        • Austin Hospital
      • Malvern, 호주, 3144
        • Cabrini Medical Centre
      • Murdoch, 호주, 6150
        • St John of God Hospital Murdoch
      • Nedlands, 호주, 6009
        • Sir Charles Gairdner Hospital
      • Westmead, 호주, 2145
        • Westmead Hospital
      • Wollongong, 호주, 2500
        • Southern Medical Day Care Centre
      • Woolloongabba, 호주, 4102
        • Princess Alexandra Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Participant must have newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation
  • The tumor harbors exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care
  • Mandatory submission of unstained tissue from tumor (in a quantity sufficient to allow for central analysis of EGFR mutation status and blood (for circulating tumor deoxyribonucleic acid [ctDNA], digital droplet polymerase chain reaction [ddPCR], and pharmacogenomic analysis)
  • Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Grade 1 or baseline level
  • Participant must have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) v1.1 that has not been previously irradiated. Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiated measurable lesion exists, it may undergo a diagnostic biopsy and be acceptable as a target lesion, provided the baseline tumor assessment scans are performed at least 14 days after the biopsy

Exclusion Criteria:

  • Participant has received any prior systemic treatment at any time for locally advanced Stage III or metastatic Stage IV disease (adjuvant or neoadjuvant therapy for Stage I or II disease is allowed, if administered more than 12 months prior to the development of locally advanced or metastatic disease)
  • Participant has an active or past medical history of leptomeningeal disease
  • Participant with untreated spinal cord compression. A participant that has been definitively treated with surgery or radiation and has a stable neurological status for at least 2 weeks prior to randomization is eligible provided they are off corticosteroid treatment or receiving low-dose corticosteroid treatment less than or equal to (<=) 10 milligrams per day (mg/day) prednisone or equivalent
  • Participant has an active or past medical history of interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis
  • Participant has known allergy, hypersensitivity, or intolerance to the excipients used in formulation of amivantamab, lazertinib, or osimertinib, or any contraindication to the use of osimertinib
  • Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment Arm A (Open-label): Amivantamab and Lazertinib

Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80*3) orally once daily.

Participants will receive amivantamab intravenously.

다른 이름들:
  • JNJ-61186372

Participants will receive lazertinib tablets orally.

다른 이름들:
  • JNJ-73841937 및 YH-25448
활성 비교기: Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib

Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80*3) orally once daily.

Participants will receive osimertinib capsules orally.

Participants will receive matching placebo orally.

실험적: Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib

Participants will receive lazertinib 240 mg (80*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.

Participants will receive lazertinib tablets orally.

다른 이름들:
  • JNJ-73841937 및 YH-25448

Participants will receive matching placebo orally.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
기간: From randomization to either disease progression or death whichever occurs first (up to 32.8 months)

PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) the absence of progression, whichever came first. Disease progression was defined using RECIST 1.1 as a 20 percent (%) increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 millimeters (mL). Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment.

From randomization to either disease progression or death whichever occurs first (up to 32.8 months)

2차 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS)
기간: Approximately 60 months (time from the date of randomization until the date of death due to any cause)

Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.

Approximately 60 months (time from the date of randomization until the date of death due to any cause)
Objective Response Rate (ORR)
기간: Approximately 32.8 months

ORR is defined as the percentage of participants who achieve either a complete response (CR) or partial response (PR) as defined by BICR using RECIST v1.1 criteria.

Approximately 32.8 months
Duration of Response (DOR)
기간: Approximately 32.8 months

DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST v1.1 criteria.

Approximately 32.8 months
Progression-Free Survival After First Subsequent Therapy (PFS2)
기간: Approximately 60 months

The PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.

Approximately 60 months
Time to Symptomatic Progression (TTSP)
기간: Approximately 60 months

TTSP is defined as the time from randomization to documentation in the electronic case report form (eCRF) of any of the following (whichever occurs earlier): onset of new symptoms or symptom worsening that is considered by the investigator to be related to lung cancer and requires either a change in anticancer treatment and/or clinical intervention to manage symptoms.

Approximately 60 months
Intracranial PFS
기간: Approximately 60 months

Intracranial PFS is defined as the time from randomization until the date of objective intracranial disease progression or death, whichever comes first, based on BICR using RECIST v1.1.

Approximately 60 months
Incidence and Severity of Adverse Events (AEs)
기간: Approximately 60 months

Incidence and severity of treatment emergent adverse events (TEAEs) will be reported. Any adverse event occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or until the start of subsequent anticancer therapy (if earlier), is considered to be treatment emergent.

Approximately 60 months
Number of Participants With Clinical Laboratory Abnormalities
기간: Approximately 60 months

Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, blood coagulation, and urine samples) will be reported.

Approximately 60 months
Number of Participants With Vital Signs Abnormalities
기간: Approximately 60 months

Number of participants with vital signs abnormalities (temperature, heart rate, respiratory rate, oxygen saturation, blood pressure) will be reported.

Approximately 60 months
Number of Participants With Physical Examination Abnormalities
기간: Approximately 60 months

Number of participants with physical examination abnormalities will be reported.

Approximately 60 months
Serum Concentration of Amivantamab
기간: Approximately 60 months

Serum samples will be analyzed to determine concentrations of Amivantamab.

Approximately 60 months
Plasma Concentration of Lazertinib
기간: Approximately 60 months

Plasma samples will be analyzed to determine concentrations of Lazertinib.

Approximately 60 months
Number of Participants With Anti-Amivantamab Antibodies
기간: Approximately 60 months

Number of participants with antibodies to amivantamab will be reported.

Approximately 60 months
Change From Baseline in Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NCSLC-SAQ)
기간: Baseline up to approximately 60 months

The NSCLC-SAQ contains 7 items that assess cough, pain, dyspnea, fatigue, and poor appetite over a 7-day recall period. Each multi-item scale and individual item will be summarized using count and percent by visit.

Baseline up to approximately 60 months
Change From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
기간: Baseline up to approximately 60 months

EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.

Baseline up to approximately 60 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 9월 30일

기본 완료 (실제)

2023년 8월 11일

연구 완료 (추정된)

2028년 2월 16일

연구 등록 날짜

최초 제출

2020년 7월 23일

QC 기준을 충족하는 최초 제출

2020년 7월 23일

처음 게시됨 (실제)

2020년 7월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CR108856
  • 2020-000743-31 (EudraCT 번호)
  • 73841937NSC3003 (기타 식별자: Janssen Research & Development, LLC)
  • 2023-506576-27-00 (레지스트리 식별자: EUCT number)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다